OCU400 (AAV5-hNR2E3)
Retinitis Pigmentosa
Phase 3Active - Enrollment Complete
Key Facts
About Ocugen
Ocugen is a clinical-stage biotech focused on developing transformative gene therapies for blindness diseases, with a lead program in Phase 3 for retinitis pigmentosa. The company leverages a unique modifier gene therapy platform designed to address multiple genetic mutations with a single treatment, offering a potential paradigm shift in ophthalmology. Ocugen also maintains a portfolio of inhaled vaccines and biologics, supported by strategic partnerships with Bharat Biotech and CanSinoBIO. The company is led by a seasoned team with deep experience in biopharmaceutical development and commercialization.
View full company profileTherapeutic Areas
Other Retinitis Pigmentosa Drugs
| Drug | Company | Phase |
|---|---|---|
| Endogena Therapeutics Program | Centenara Labs | Phase 1b/2a |